Do PAI-1 and Vitronectin Promote or Inhibit Neointima Formation?
- 1 December 2002
- journal article
- editorial
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 22 (12) , 1943-1945
- https://doi.org/10.1161/01.atv.0000047462.65341.22
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Different Mechanisms of Increased Luminal Stenosis After Arterial Injury in Mice Deficient for Urokinase- or Tissue-Type Plasminogen ActivatorCirculation, 2002
- Vitronectin Functions as a Cofactor for Rapid Inhibition of Activated Protein C by Plasminogen Activator Inhibitor-1Journal of Biological Chemistry, 2001
- Remodeling of the Vessel Wall after Copper-Induced Injury Is Highly Attenuated in Mice with a Total Deficiency of Plasminogen Activator Inhibitor-1The American Journal of Pathology, 2001
- PAI-1, fibrosis, and the elusive provisional fibrin matrixJournal of Clinical Investigation, 2000
- Type 1 Plasminogen Activator Inhibitor Binds to Fibrin via VitronectinJournal of Biological Chemistry, 2000
- Fibrinogen deficiency is compatible with the development of atherosclerosis in mice.Journal of Clinical Investigation, 1998
- The serpin PAI-1 inhibits cell migration by blocking integrin αvβ3 binding to vitronectinNature, 1996
- Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?The Journal of cell biology, 1996
- Increased intramural expression of plasminogen activator inhibitor type 1 after balloon injury: A potential progenitor of restenosisJournal of the American College of Cardiology, 1994
- PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTIONThe Lancet, 1987